A Phase 3 interventional study of albiglutide and sitagliptin in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 218 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-28.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of diet and exercise or their antidiabetic therapy of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic medications will be recruited into the study.
This randomized, double-blind, active-controlled, 2 parallel-group, multicenter study evaluates the efficacy and safety of a weekly subcutaneously injected dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of diet and exercise or their antidiabetic therapy of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic medications will be recruited into the study.
1,995 studies on the registry are indexed under Renal Insufficiency; 173 are open to participants now.
This study's enrollment of 507 is above the median of 43 across 1,504 interventional studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
albiglutide weekly subcutaneous injection + sitagliptin matching placebo
Biological: albiglutide
albiglutide matching placebo + sitagliptin
Drug: sitagliptin
albiglutide weekly subcutaneous injection + sitagliptin matching placebo
albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the value at Week 26 minus the value at Baseline. The analysis was performed using an Analysis of Covariance (ANCOVA) model with treatment group, region, history of prior myocardial infarction (yes versus no), and age category (\<65 years versus \>=65 years) as factors and Baseline HbA1c as a continuous covariate. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Baseline; Week 26
Mean Change From Baseline in HbA1c at Weeks 4, 8, 12, 16, and 20: LOCF
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
Time frame: Baseline; Weeks 4, 8, 12, 16, and 20
Mean Change From Baseline in HbA1c at Weeks 4, 8, 12, 16, 20, 26, 36, 48, and Week 52: Observed Cases
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the post-Baseline value minus the Baseline value. The Observed Cases (OC) method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
Time frame: Baseline; Weeks 4, 8, 12, 16, 20, 26, 36, 48, and 52
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is define as the last non-missing value before the start of treatment. Change from Baseline in FBG was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week. Based on ANCOVA: Change = treatment + Baseline FPG + renal impairment + prior myocardial infarction history + age category + region.
Time frame: Baseline; Week 26
Mean Change From Baseline in FPG at Weeks 4, 8, 12, 16, 20, and 26: LOCF
The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline in FBG was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
Time frame: Baseline; Weeks 4, 8, 12, 16, 20, and 26
Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 1, 2, 3, 4, 8, 12, 16, 20, 26, 36, 48, and Week 52: OC
The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is defined as the last non-missing value prior to treatment. Change from Baseline in FBG was calculated as the post-Baseline value minus the Baseline value. The OC method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
Time frame: Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 26, 36, 48, Week 52
Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5% and <7.0% at Week 26: LOCF
The number of participants who acheieved the HbA1c treatment goal (i.e., the number of participants who achieved HbA1c \<7% and \<6.5% at Week 26) was assessed. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Week 26
Number of Participants Who Achieved a Clinically Meaningful Improvement in the HbA1c Response Level of >=1.0%, >=1.5%, and >=2.0% at Week 26: LOCF
The number of participants who a clinically meaningful improvement from Baseline in the HbA1c response level of \>=1.0%, \>=1.5%, and \>=2.0% at Week 26 were assessed. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Week 26
Number of Participants Who Achieved a Clinically Meaningful HbA1c Response Level of <6.5% and <7.0% at Week 52: OC
The number of participants who acheieved the HbA1c treatment goal (i.e., number of participants who achieved HbA1c \<7% and \<6.5% at Week 26) was assessed. The OC method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Week 52
Number of Participants Who Achieved a Clinically Meaningful Improvement in the HbA1c Response Level of >=1.0%, >=1.5%, and >=2.0% at Week 52: OC
The number of participants who a clinically meaningful improvement from Baseline in the HbA1c response level of \>=1.0%, \>=1.5%, and \>=2.0% at Week 52 assessed. The OC method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Time frame: Week 52
Number of Participants With the Indicated Time to Hyperglycemic Rescue Through Week 52
Hyperglycemic rescue was defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days and analyzed by the central laboratory: for the Week 2 to Week 4 visit, a single FPG value \>=280 milligrams per deciliter (mg/dL); for the \>Week 4 and \<Week 12 visits, a single FPG value \>=250 mg/dL and previous titration for \>=4 weeks; for the \>=Week 12 and \<Week 26 visits, HbA1c \>=8.5% and a \<=0.5% reduction from Baseline and previous titration for \>=4 weeks; for the \>=Week 26 and \<Week 48 visits, HbA1c \>=8.5% and previous titration for \>=4 weeks; for the \>=Week 48 and \<Week 52 visits, HbA1c \>=8.0% and previous titration for \>=4 weeks. Time to hyperglycemia rescue is the time between the date of first dose and the date of hyperglycemia rescue plus 1 day, or the time between the date of first dose and the date of last visit during active treatment period plus 1 day for participants not requiring rescue.
Time frame: Week 2 to Week 52
Time to Hyperglycemic Rescue Through Week 52
Hyperglycemic rescue was defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days and analyzed by the central laboratory: for the Week 2 to Week 4 visit, a single FPG value \>=280 milligrams per deciliter (mg/dL); for the \>Week 4 and \<Week 12 visits, a single FPG value \>=250 mg/dL and previous titration for \>=4 weeks; for the \>=Week 12 and \<Week 26 visits, HbA1c \>=8.5% and a \<=0.5% reduction from Baseline and previous titration for \>=4 weeks; for the \>=Week 26 and \<Week 48 visits, HbA1c \>=8.5% and previous titration for \>=4 weeks; for the \>=Week 48 and \<Week 52 visits, HbA1c \>=8.0% and previous titration for \>=4 weeks. Time to hyperglycemia rescue is the time between the date of first dose and the date of hyperglycemia rescue plus 1 day, or the time between the date of first dose and the date of last visit during active treatment period plus 1 day for participants not requiring rescue. This time is divided by 7 to express the result in weeks.
Time frame: Week 2 to Week 52
Change From Baseline in Body Weight at Week 26: LOCF
Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The Baseline weight value is defined as the last non-missing value prior to treatment. This analysis used the LOCF method for missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue werre treated as missing and were replaced with pre-rescue values. Based on ANCOVA: Change = treatment + Baseline weight + renal impairment + prior myocardial infarction history + age category + region.
Time frame: Baseline; Week 26
Change From Baseline in Body Weight Through Week 26: LOCF
Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The Baseline weight value is defined as the last non-missing value prior to treatment. This analysis used the LOCF method for missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue werre treated as missing and were replaced with pre-rescue values.
Time frame: Baseline; Week 1, Week 2 , Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 26
Change From Baseline in Body Weight Through Week 52: OC
Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The Baseline weight value is defined as the last non-missing value prior to treatment. This analysis used observed weight values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed.
Time frame: Baseline; Week 1, Week 2 , Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, Week 26, Week 36, Week 48, and Week 52
Plasma Concentrations (Conc.) of Albiglutide at Week 8 and Week 16
Sparse population pharmacokinetic (PK) data were collected for population PK and PK/pharmacodynamic (PD) analyses. Participants (par.) who received albiglutide were initiated on a 30 mg weekly dosing regimen. Beginning at Week 4, uptitration of albiglutide was allowed based on glycemic parameters. As such, albiglutide plasma conc. achieved at each sampling time represent a mixed population of par. who received either 30 mg or 50 mg weekly for various durations. The PK and PK/PD of albiglutide were characterized using a population modeling approach. Mean albiglutide plasma conc. observed at Weeks 8 and 16 are presented. Par. came to the clinic at Weeks 8 and 16 without taking albiglutide/matching placebo. The pre-dose PK sample was taken immediately prior to dosing. The Week 8 post-dose sample was taken between Weeks 8 and 10, \>=2 days after a dose of medication. The Week 16 post-dose PK sample was taken any time between Weeks 16 and 20, \>=2 days after the previous dose of albiglutide.
Time frame: Week 8 Pre-dose (immediately prior to dose), Week 8 Post-dose (at least 2 days after a dose of medication), Week 16 Pre-dose (immediately prior to dose), and Week 16 Post-dose (at least 2 days after previous dose of albiglutide)
| Milestone | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Started | 249 | 246 |
| Completed | 198 | 178 |
| Not completed | 51 | 68 |
| Withdrew: Adverse event | 26 | 26 |
| Withdrew: Protocol violation | 1 | 4 |
| Withdrew: Noncompliance | 3 | 5 |
| Withdrew: Lost to follow-up | 4 | 4 |
| Withdrew: Withdrawal by subject | 12 | 26 |
| Withdrew: Physician decision | 5 | 3 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the value at Week 26 minus the value at Baseline. The analysis was performed using an Analysis of Covariance (ANCOVA) model with treatment group, region, history of prior myocardial infarction (yes versus no), and age category (\<65 years versus \>=65 years) as factors and Baseline HbA1c as a continuous covariate. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
| Percentage of HbA1c in the blood | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 | -0.83 ± 0.062 | -0.52 ± 0.063 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
| Percentage of HbA1c in the blood | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Week 4, n=237, 234 | -0.43 ± 0.460 | -0.37 ± 0.512 |
| Week 8, n=242, 236 | -0.60 ± 0.663 | -0.52 ± 0.785 |
| Week 12, n=242, 236 | -0.69 ± 0.840 | -0.56 ± 0.989 |
| Week 16, n=242, 236 | -0.75 ± 0.886 | -0.56 ± 1.103 |
| Week 20, n=242, 236 | -0.79 ± 0.890 | -0.54 ± 1.083 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the post-Baseline value minus the Baseline value. The Observed Cases (OC) method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
| Percentage of HbA1c in the blood | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Week 4, n=233, 228 | -0.43 ± 0.463 | -0.37 ± 0.512 |
| Week 8, n=222, 213 | -0.63 ± 0.677 | -0.56 ± 0.794 |
| Week 12, n=224, 216 | -0.71 ± 0.832 | -0.62 ± 0.940 |
| Week 16, n=218, 209 | -0.75 ± 0.885 | -0.63 ± 1.085 |
| Week 20, n=207, 196 | -0.86 ± 0.852 | -0.71 ± 0.931 |
| Week 26, n=202, 178 | -0.93 ± 0.806 | -0.80 ± 0.887 |
| Week 36, n=192, 155 | -1.01 ± 0.808 | -0.82 ± 1.014 |
| Week 48, n=172, 139 | -1.01 ± 0.884 | -0.89 ± 0.977 |
| Week 52, n=157, 118 | -1.04 ± 0.796 | -1.03 ± 0.883 |
The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is define as the last non-missing value before the start of treatment. Change from Baseline in FBG was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week. Based on ANCOVA: Change = treatment + Baseline FPG + renal impairment + prior myocardial infarction history + age category + region.
| Millimoles per liter (mmol/L) | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | -1.42 ± 0.183 | -0.22 ± 0.184 |
The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline in FBG was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
| Millimoles per liter (mmol/L) | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Week 4, n=244, 240 | -1.47 ± 3.054 | -0.84 ± 2.670 |
| Week 8, n=244, 240 | -1.19 ± 3.115 | -0.82 ± 3.169 |
| Week 12, n=244, 240 | -1.35 ± 2.930 | -0.81 ± 3.214 |
| Week 16, n=244, 240 | -1.34 ± 3.070 | -0.49 ± 3.440 |
| Week 20, n=244, 240 | -1.37 ± 3.198 | -0.62 ± 3.257 |
The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is defined as the last non-missing value prior to treatment. Change from Baseline in FBG was calculated as the post-Baseline value minus the Baseline value. The OC method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
| Millimoles per liter (mmol/L) | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Week 1, n=219, 217 | -0.82 ± 2.572 | -0.93 ± 2.207 |
| Week 2, n=226, 223 | -1.28 ± 2.569 | -0.66 ± 2.319 |
| Week 3, n=230, 219 | -1.25 ± 3.168 | -0.88 ± 2.136 |
| Week 4, n=231, 226 | -1.55 ± 2.859 | -0.76 ± 2.569 |
| Week 8, n=221, 210 | -1.24 ± 2.896 | -0.74 ± 2.877 |
| Week 12, n=224, 216 | -1.46 ± 2.623 | -0.88 ± 2.723 |
| Week 16, n=214, 204 | -1.41 ± 2.796 | -0.55 ± 3.023 |
| Week 20, n=207, 191 | -1.51 ± 2.859 | -1.00 ± 2.474 |
| Week 26, n=200, 177 | -1.54 ± 2.507 | -0.58 ± 2.673 |
| Week 36, n=186, 149 | -1.42 ± 2.788 | -0.92 ± 2.628 |
| Week 48, n=165, 140 | -1.08 ± 2.720 | -0.58 ± 2.725 |
| Week 52, n=149, 114 | -1.06 ± 2.850 | -0.96 ± 2.281 |
The number of participants who acheieved the HbA1c treatment goal (i.e., the number of participants who achieved HbA1c \<7% and \<6.5% at Week 26) was assessed. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
| Participants | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| HbA1c <6.5% | 37 | 29 |
| HbA1c <7.0% | 103 | 72 |
The number of participants who a clinically meaningful improvement from Baseline in the HbA1c response level of \>=1.0%, \>=1.5%, and \>=2.0% at Week 26 were assessed. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
| Participants | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| HbA1c >=1.0% | 102 | 77 |
| HbA1c >=1.5% | 49 | 38 |
| HbA1c >=2.0% | 26 | 17 |
The number of participants who acheieved the HbA1c treatment goal (i.e., number of participants who achieved HbA1c \<7% and \<6.5% at Week 26) was assessed. The OC method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
| Participants | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| HbA1c <6.5% | 44 | 27 |
| HbA1c <7.0% | 98 | 61 |
The number of participants who a clinically meaningful improvement from Baseline in the HbA1c response level of \>=1.0%, \>=1.5%, and \>=2.0% at Week 52 assessed. The OC method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
| Participants | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| HbA1c >=1.0% | 79 | 65 |
| HbA1c >=1.5% | 43 | 30 |
| HbA1c >=2.0% | 20 | 15 |
Hyperglycemic rescue was defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days and analyzed by the central laboratory: for the Week 2 to Week 4 visit, a single FPG value \>=280 milligrams per deciliter (mg/dL); for the \>Week 4 and \<Week 12 visits, a single FPG value \>=250 mg/dL and previous titration for \>=4 weeks; for the \>=Week 12 and \<Week 26 visits, HbA1c \>=8.5% and a \<=0.5% reduction from Baseline and previous titration for \>=4 weeks; for the \>=Week 26 and \<Week 48 visits, HbA1c \>=8.5% and previous titration for \>=4 weeks; for the \>=Week 48 and \<Week 52 visits, HbA1c \>=8.0% and previous titration for \>=4 weeks. Time to hyperglycemia rescue is the time between the date of first dose and the date of hyperglycemia rescue plus 1 day, or the time between the date of first dose and the date of last visit during active treatment period plus 1 day for participants not requiring rescue.
| Participants | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Week 2 | 0 | 2 |
| Week 4 | 0 | 2 |
| Week 8 | 1 | 3 |
| Week 12 | 2 | 5 |
| Week 16 | 5 | 6 |
| Week 20 | 9 | 14 |
| Week 26 | 15 | 29 |
| Week 36 | 25 | 47 |
| Week 48 | 33 | 53 |
| Week 52 | 44 | 68 |
Hyperglycemic rescue was defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days and analyzed by the central laboratory: for the Week 2 to Week 4 visit, a single FPG value \>=280 milligrams per deciliter (mg/dL); for the \>Week 4 and \<Week 12 visits, a single FPG value \>=250 mg/dL and previous titration for \>=4 weeks; for the \>=Week 12 and \<Week 26 visits, HbA1c \>=8.5% and a \<=0.5% reduction from Baseline and previous titration for \>=4 weeks; for the \>=Week 26 and \<Week 48 visits, HbA1c \>=8.5% and previous titration for \>=4 weeks; for the \>=Week 48 and \<Week 52 visits, HbA1c \>=8.0% and previous titration for \>=4 weeks. Time to hyperglycemia rescue is the time between the date of first dose and the date of hyperglycemia rescue plus 1 day, or the time between the date of first dose and the date of last visit during active treatment period plus 1 day for participants not requiring rescue. This time is divided by 7 to express the result in weeks.
| Weeks | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Time to Hyperglycemic Rescue Through Week 52 | NA (NA to NA) | NA (NA to NA) |
Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The Baseline weight value is defined as the last non-missing value prior to treatment. This analysis used the LOCF method for missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue werre treated as missing and were replaced with pre-rescue values. Based on ANCOVA: Change = treatment + Baseline weight + renal impairment + prior myocardial infarction history + age category + region.
| Kilograms | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Change From Baseline in Body Weight at Week 26: LOCF | -0.79 ± 0.192 | -0.19 ± 0.194 |
Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The Baseline weight value is defined as the last non-missing value prior to treatment. This analysis used the LOCF method for missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue werre treated as missing and were replaced with pre-rescue values.
| Kilograms | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Week 1, n=225, 225 | -0.17 ± 1.215 | 0.12 ± 1.237 |
| Week 2, n=241, 238 | -0.21 ± 1.317 | -0.02 ± 1.423 |
| Week 3, n=244, 240 | -0.25 ± 1.392 | 0.01 ± 1.530 |
| Week 4, n=244, 240 | -0.33 ± 1.456 | 0.09 ± 1.806 |
| Week 8, n=244, 240 | -0.58 ± 1.768 | 0.02 ± 1.952 |
| Week 12, n=244, 240 | -0.47 ± 2.055 | 0.03 ± 2.254 |
| Week 16, n=244, 240 | -0.63 ± 2.197 | -0.08 ± 2.564 |
| Week 20, n=244, 240 | -0.69 ± 2.556 | -0.07 ± 2.878 |
Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The Baseline weight value is defined as the last non-missing value prior to treatment. This analysis used observed weight values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed.
| Kilograms | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Week 1, n=225, 225 | -0.17 ± 1.215 | 0.12 ± 1.237 |
| Week 2, n=232, 227 | -0.21 ± 1.339 | -0.01 ± 1.438 |
| Week 3, n=236, 224 | -0.24 ± 1.404 | 0.03 ± 1.544 |
| Week 4, n=235, 230 | -0.31 ± 1.466 | 0.10 ± 1.827 |
| Week 8, n=226, 214 | -0.61 ± 1.800 | 0.05 ± 2.012 |
| Week 12, n=228, 219 | -0.45 ± 2.091 | 0.16 ± 2.193 |
| Week 16, n=223, 210 | -0.68 ± 2.226 | 0.07 ± 2.589 |
| Week 20, n=211, 198 | -0.76 ± 2.619 | 0.09 ± 2.976 |
| Week 26, n=202, 178 | -0.87 ± 2.856 | -0.04 ± 3.465 |
| Week 36, n=190, 155 | -0.92 ± 3.551 | 0.01 ± 2.975 |
| Week 48, n=172, 140 | -0.93 ± 3.829 | 0.07 ± 3.349 |
| Week 52, n=157, 119 | -0.82 ± 3.931 | 0.31 ± 3.685 |
Sparse population pharmacokinetic (PK) data were collected for population PK and PK/pharmacodynamic (PD) analyses. Participants (par.) who received albiglutide were initiated on a 30 mg weekly dosing regimen. Beginning at Week 4, uptitration of albiglutide was allowed based on glycemic parameters. As such, albiglutide plasma conc. achieved at each sampling time represent a mixed population of par. who received either 30 mg or 50 mg weekly for various durations. The PK and PK/PD of albiglutide were characterized using a population modeling approach. Mean albiglutide plasma conc. observed at Weeks 8 and 16 are presented. Par. came to the clinic at Weeks 8 and 16 without taking albiglutide/matching placebo. The pre-dose PK sample was taken immediately prior to dosing. The Week 8 post-dose sample was taken between Weeks 8 and 10, \>=2 days after a dose of medication. The Week 16 post-dose PK sample was taken any time between Weeks 16 and 20, \>=2 days after the previous dose of albiglutide.
| nanograms per milliliter (ng/mL) | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Week 8, Pre-dose, n=223 | 3005.80 ± 1788.544 | — |
| Week 8, Post-dose, n=220 | 3452.62 ± 1912.329 | — |
| Week 16, Pre-dose, n=215 | 2994.15 ± 1759.161 | — |
| Week 16, Post-dose, n=205 | 3583.06 ± 2239.026 | — |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the time of study participation consent through Week 60, or the final follow-up visit for participants who discontinued active participation in the study (up to Study Week 60).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Albiglutide 30 mg | — | 30/249 (12%) | 174/249 (69.9%) |
| Sitagliptin 100 mg | — | 33/246 (13.4%) | 162/246 (65.9%) |
| Event | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| Atrial fibrillationCardiac disorders | 4/249 | 1/246 |
| GastroenteritisInfections and infestations | 0/249 | 3/246 |
| Ischaemic strokeNervous system disorders | 0/249 | 3/246 |
| PneumoniaInfections and infestations | 1/249 | 2/246 |
| Vitreous haemorrhageEye disorders | 0/249 | 2/246 |
| Urinary tract infectionInfections and infestations | 2/249 | 0/246 |
| Cerebrovascular accidentNervous system disorders | 2/249 | 1/246 |
| HaematuriaRenal and urinary disorders | 2/249 | 0/246 |
| Coronary artery diseaseCardiac disorders | 1/249 | 1/246 |
| Angina pectorisCardiac disorders | 0/249 | 1/246 |
| Event | Albiglutide 30 mg | Sitagliptin 100 mg |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 60/249 | 39/246 |
| DiarrhoeaGastrointestinal disorders | 25/249 | 16/246 |
| Upper respiratory tract infectionInfections and infestations | 14/249 | 23/246 |
| Urinary tract infectionInfections and infestations | 21/249 | 20/246 |
| NasopharyngitisInfections and infestations | 14/249 | 20/246 |
| HypertensionVascular disorders | 14/249 | 19/246 |
| AnaemiaBlood and lymphatic system disorders | 16/249 | 10/246 |
| ConstipationGastrointestinal disorders | 15/249 | 6/246 |
| Oedema peripheralGeneral disorders | 13/249 | 8/246 |
| NauseaGastrointestinal disorders | 12/249 | 8/246 |
| Age, Continuous(Years) | Albiglutide 30 mg | Sitagliptin 100 mg | Total |
|---|---|---|---|
| Mean | 63.2 ± 8.37 | 63.5 ± 9.02 | 63.3 ± 8.69 |
| Gender(Participants) | Albiglutide 30 mg | Sitagliptin 100 mg | Total |
|---|---|---|---|
| Female | 113 | 116 | 229 |
| Male | 136 | 130 | 266 |
| Race/Ethnicity, Customized(Participants) | Albiglutide 30 mg | Sitagliptin 100 mg | Total |
|---|---|---|---|
| African American/African Heritage | 36 | 42 | 78 |
| American Indian or Alaskan Native | 16 | 16 | 32 |
| Asian - Central/South Asian Heritage | 45 | 33 | 78 |
| Asian - East Asian Heritage | 26 | 29 | 55 |
| Asian - South East Asian Heritage | 13 | 14 | 27 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| White - Arabic/North African Heritage | 0 | 1 | 1 |
| White - White/Caucasian/European Heritage | 112 | 111 | 223 |
Showing the first 100 of 218 sites across 15 countries.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline